Competitive intelligence for medical devices

What competitive intelligence means in medical devices

In most industries competitive intelligence is about product and price. In medical devices there is a third axis that decides outcomes: permission. A competitor needs a regulatory route to sell and a payment route to earn. Either one can be the constraint, and the public record shows both. That is unusual, and it is the reason device competitive intelligence can be far more precise than the equivalent work in other sectors — if you read the right sources.

The failure mode is collecting without deciding. Teams subscribe to a feed, circulate clearance alerts, and six months later cannot say which market they should have entered. The fix is to put a scoring step between the signal and the slide: every finding lands as a change in a competitor threat score or a market score, and every score has visible inputs. A clearance that does not move a score is context, not intelligence.

Intelligence feeds versus scoring-based decision support

The established competitive intelligence vendors in life sciences — Clarivate, Valona and the specialist analyst shops — are good at breadth and at summarising. What they hand back is material. What a device team needs at the end of the quarter is a decision: which market, at what price, with what evidence. The table below is the honest split between the two, and it explains where a scoring layer earns its place.

If you want the detail on how the scoring side is built — factors, weights, and how reimbursement friendliness is treated — read how MedTech Compass works and the medical device market intelligence overview.

Building a watchlist and a review cadence

A watchlist is not a list of companies. It is a list of companies plus the specific records you will check for each of them: product codes, device names, certificate holders, code sets. Written that way it survives staff changes and it can be handed to a junior analyst without losing fidelity.

The cadence that works for most teams is a weekly ten-minute sweep of the fast databases, a monthly written review, and a quarterly refresh of payment positions. The monthly review has four standing items: new clearances and certificates, new payment moves, changes to threat and market scores, and one decision — taken or explicitly deferred. Our regulatory news feed covers the FDA, CMS and EU updates automatically, which removes most of the weekly sweep.

Interactive competitive intelligence tools

Four tools you can use straight away. Everything runs in your browser — nothing is stored, sent or logged, and you do not need an account.

COMPETITIVE INTELLIGENCE BRIEF
==============================
Decision: Enter a market
Competitor set: Three to five rivals
Markets in scope: United States, European Union

1. DECISION STATEMENT
   - One sentence: the decision this brief must support, and by when.
   - The option set being compared, including the option to do nothing.

2. COMPETITOR SET AND SCOPE
   - Three to five rivals in a single table: devices, pathway, markets, payment route.
   - Rank by threat score rather than by revenue estimate.

3. REGULATORY SIGNALS
   - Clearances, approvals and certificates in the last 24 months, with dates.
   - Product codes and predicate chains, and what they imply about route and speed.
   - Recalls, field actions and adverse event patterns.

4. REIMBURSEMENT AND MARKET ACCESS
   - Payment route in each market in scope: code, rate, coverage status, evidence needed.
   - Whether the rival is paid, or cleared but unpaid — state which, explicitly.

5. EVIDENCE AND CLINICAL POSITION
   - Published studies, registries, guideline or society mentions.
   - Gaps in their evidence that your evidence plan could exploit.

6. COMMERCIAL POSITION
   - Distribution, integrations, installed base, tenders and partnerships.
   - Pricing observed, and the switching cost they impose on customers.

7. SCORING
   - Threat score per rival, with the factor breakdown attached.
   - Market score per market in scope: pathway difficulty, reimbursement friendliness, competitor density, size.
   - What changed since the last review, and why.

8. DECISION-SPECIFIC ANALYSIS
   - Ranked markets with the entry cost and time to first payment for each.
   - The market where competitor density is lowest relative to reimbursement friendliness.
   - Sequencing: which market first, which second, and the trigger to move.

9. RECOMMENDATION
   - The recommended option in one sentence, with the two facts that most support it.
   - The single assumption that, if wrong, reverses the recommendation.

10. WATCH LIST AND CADENCE
   - Sources to monitor and how often, per market.
   - Trigger events that force an early re-run of this brief.
   - Owner and next review date.

Sources: cite the official database record for every regulatory and payment claim.

These tools are educational. They are not regulatory, legal or investment advice, and they do not replace review by a qualified professional.

Frequently asked questions

What is competitive intelligence for medical devices?

It is the disciplined collection and interpretation of public signals about the devices you compete with: regulatory clearances and certificates, recalls and adverse event patterns, labelled indications, reimbursement coverage and payment rates, clinical evidence, and commercial moves such as funding, tenders and distribution deals. The purpose is not a competitor list. It is a decision — which market to enter, what to price, what evidence to fund, and where you are exposed.

How is it different from market research?

Market research sizes a category and describes buyer behaviour, usually on a slow cadence. Competitive intelligence tracks named competitors on a fast cadence and is judged on whether it changes a decision. In devices the two meet at market access: a competitor with a payment pathway in a market you cannot get paid in is a strategic fact, not a research footnote.

Which databases should I monitor?

For the US: the 510(k), De Novo and PMA databases, the recall database, MAUDE adverse events, and the openFDA device APIs if you want to automate. For Europe: EUDAMED and the NANDO notified body list. For payment: CMS coding and payment files, NICE guidance in the UK, and the BfArM DiGA directory in Germany. The signal source planner on this page builds the list for your device type and markets.

How do the commercial intelligence vendors compare?

Vendors such as Clarivate, Valona and similar market-intelligence providers are strong at breadth: aggregated feeds, analyst summaries and coverage across life sciences. What they generally leave to you is the decision layer — a repeatable score that says whether a specific market is worth entering for a specific device, with reimbursement friendliness and pathway difficulty carried through to a number you can compare. That is the gap MedTech Compass fills.

How often should a competitive intelligence review run?

Match the cadence to the source. Clearance and recall databases justify a weekly scan because they change weekly. Certificates, coverage decisions and payment files move quarterly. A monthly written review with a standing agenda works for most teams: new clearances, new payment moves, changes in your threat scores, and one decision to take or defer.

Does a competitor clearance mean they have market share?

No, and treating it that way is the most common mistake in this discipline. A clearance is permission to sell. Revenue needs a payment pathway, a buyer with a budget line, and a workflow someone will change. Plenty of cleared AI-enabled devices sit with no established payment route, which is exactly why competitive intelligence in devices has to carry reimbursement signals alongside regulatory ones.

Can competitive intelligence be automated?

Collection largely can. The FDA databases publish machine-readable data and EUDAMED is public. Interpretation is the part that fails when automated blindly: matching a product code to a genuine competitor, judging whether an indication overlaps yours, and weighting a payment change all need a human with product context. Automate the sweep, keep the scoring explicit, and record why a score changed.

How does this connect to market scoring?

Competitor density is one input to a market score, alongside regulatory pathway difficulty, reimbursement friendliness and market size. Scoring forces the comparison to be consistent: the same factors, the same weights, across every market you consider. MedTech Compass applies that scoring across 25+ markets so that a competitive finding lands as a change in a market ranking rather than a slide in a deck.